U.S. Pharma Stock News

Why Yalla Group (YALA) is back on investors’ radar Yalla Group (YALA) has drawn fresh attention after its board approved a new share repurchase program of up to US$150 million, alongside first quarter 2026 revenue guidance that factors in the timing of Ramadan. See our latest analysis for Yalla Group. Those moves come after a period where the 1 year total shareholder return of 76.9% contrasts with a more muted 0.7% year to date share price return at US$7.11, suggesting recent momentum has...

In Q2 2025, Mettler-Toledo International reported marginal revenue growth but weaker gross and operating margins as higher tariffs and macroeconomic pressures weighed on profitability, and management issued cautious full-year 2025 guidance. Even as near-term earnings face pressure, the company is emphasizing bioprocessing and manufacturing onshoring as areas it believes could reshape its longer-term business mix. We’ll now examine how the tariff-driven margin squeeze highlighted in the...

Exact Sciences, Amalgam Rx and Privia Health report materially higher colorectal cancer screening rates using EHR-enabled outreach and at home noninvasive tests. The coordinated program is described as scalable and has surpassed national screening benchmarks during Colorectal Cancer Awareness Month. The initiative focuses on closing screening gaps by embedding screening prompts and workflows directly into clinical systems and patient communications. For investors watching NasdaqCM:EXAS,...

Why Nurix Therapeutics (NRIX) moved after its latest capital move Nurix Therapeutics (NRIX) recently expanded its equity distribution agreement, giving it room to sell up to $413.65 million of common stock through Piper Sandler. This step directly affects its capital-raising flexibility and potential dilution. See our latest analysis for Nurix Therapeutics. The capital plan arrives after a tougher few months for the share price, with a 30 day share price return showing an 8% decline and a 90...

In February 2026, Axogen, Inc. reported past full-year 2025 results, with sales rising to US$225.21 million from US$187.34 million, while net loss widened to US$15.70 million and basic loss per share from continuing operations increased to US$0.34 from US$0.23. On the same date, Axogen issued new 2026 guidance calling for at least 18% revenue growth to about US$265.70 million and gross margins between 74% and 76%, highlighting management’s confidence in the underlying demand for its nerve...

On February 25, 2026, Bristow Group Inc. reported fourth-quarter 2025 sales of US$377.26 million and net income of US$18.42 million, alongside a US$0.125 quarterly dividend and affirmed 2026 revenue guidance of US$1.58 billion to US$1.69 billion. The combination of stronger full-year 2025 profitability, reiterated revenue expectations for 2026, and continued cash returns via dividends underscores management’s confidence in Bristow’s operating outlook. With 2026 revenue guidance now on the...

Recent share performance and what it means for Plexus (PLXS) investors Plexus (PLXS) has caught investor attention after a strong past 3 months, with a total return above 20% and a 1 year return above 50%, despite a weaker month. That mix of shorter term softness and stronger longer term gains raises a practical question for you as an investor: whether the current share price around $191.58 still lines up with the company’s fundamentals. See our latest analysis for Plexus. Recent trading has...

ACCO Brands (ACCO) has reported its FY 2025 third quarter with revenue of US$383.7 million and EPS of US$0.04, alongside net income of US$4 million. The trailing 12 month figures show revenue of US$1.54 billion and EPS of US$0.44 supported by net income of US$40.6 million. Over recent quarters the company has seen revenue move from US$438.3 million with EPS of a US$1.29 loss and a net loss of US$125.2 million in Q2 2024 to US$394.8 million with EPS of US$0.32 and net income of US$29.2 million...

Why Nuvalent’s latest results are in focus Nuvalent (NUVL) is back on investors’ radar after reporting a fourth quarter net loss of US$118.71 million and a full-year net loss of US$425.38 million, along with a new US$458.37 million shelf registration filing. See our latest analysis for Nuvalent. At a share price of US$102.32, Nuvalent has seen a 1-day share price return of 2.93% and a year-to-date share price return of 1.47%. Its 1-year total shareholder return of 51.86% and very large 3-year...

Wondering if Starbucks at around US$99.77 is offering you real value today, or if the easy money has already been made? You are not alone in asking whether the current price lines up with what the business is actually worth. The stock has returned 3.1% over the last 7 days, 0.3% over the last 30 days and 18.8% year to date, with a 1.4% return over 1 year, 8.4% over 3 years and 2.8% over 5 years, which gives investors a mixed set of signals about recent momentum and changing risk...

Trimble is supplying technology for the Paris Grand construction project, keeping the company tied to one of Europe’s highest profile infrastructure builds. At the same time, company insiders have been consistently selling shares of NasdaqGS:TRMB over the past year, with no insider purchases reported. These two threads, project execution in France and insider activity at home, give investors fresh information on Trimble beyond recent earnings headlines. Trimble, trading at $70.45, sits at...

Amprius Technologies (NYSE:AMPX) reported record fourth quarter revenue. The company highlighted broad adoption of its second generation SiCore silicon anode batteries. Nokia Drone Networks selected Amprius SiCore batteries, adding a high profile commercial reference. Amprius said it is ahead of schedule on NDAA compliance, improving eligibility for future U.S. government contracts. Amprius focuses on high performance silicon anode batteries aimed at applications where weight, power, and...

If you are wondering whether Pinnacle Financial Partners is offering fair value at its current share price, you are not alone. This article is designed to help you frame that question clearly. The stock last closed at US$87.29, with returns of a 5.8% decline over 7 days, a 14.6% decline over 30 days, an 8.2% decline year to date, an 11.1% decline over 1 year, 58.6% over 3 years, and 1.1% over 5 years, which gives a mixed picture of recent and longer term performance. Recent news around...

Roblox has launched two new creator programs, Roblox Incubator and Roblox Jumpstart, aimed at helping developers build higher quality games for a more mature audience. The company has also rolled out AI-powered chat moderation that can automatically rephrase inappropriate messages in real time to help keep conversations safer and more civil. Roblox, listed as NYSE:RBLX, is introducing these creator programs and AI tools at a time when its share price is $62.65. The stock has seen a 16.5%...

Heritage Insurance Holdings (HRTG) just posted its FY 2025 third quarter results, reporting revenue of US$212.5 million and basic EPS of US$1.63, alongside a combined ratio of 72.9%. This puts underwriting performance in clear focus. The company’s quarterly revenue has moved in a tight band, from US$210.3 million in Q4 2024 to US$212.5 million in Q3 2025, while basic EPS increased from US$0.66 to US$1.63 over the same period. This sets the scene for investors to examine how margins and...

FuelCell Energy (FCEL) has opened Q1 2026 earnings season with Q4 2025 numbers that show total revenue of US$55.0 million and a basic EPS loss of US$0.85, alongside net income excluding extra items of a US$30.7 million loss. Over the past few quarters, the company has seen revenue move from US$23.7 million in Q3 2024 to US$49.3 million in Q4 2024 and then to US$55.0 million in Q4 2025. Quarterly basic EPS stayed in loss territory, ranging from a US$2.21 loss per share in Q4 2024 to a US$3.78...

In early March 2026, Smith & Wesson Brands, Inc. reported that its third-quarter sales rose to US$135.71 million and net income to US$3.75 million, while affirming a quarterly dividend of US$0.13 per share payable on April 2, 2026. An interesting contrast is that, despite higher quarterly sales and earnings year on year, net income for the first nine months fell to US$2.26 million from US$4.79 million, highlighting pressure on profitability over the longer period. We’ll explore how the...

Guidewire Software (NYSE:GWRE) reported a strong quarter with record revenue and rising demand for its cloud and AI products. The company secured significant new cloud customer wins and saw broader uptake of its AI driven offerings across insurers. Management raised the full year outlook and authorized a $500 million share buyback program, signaling confidence in the business. For investors watching insurance technology, Guidewire sits at the center of core systems, cloud migration, and...

Wondering whether Covista is priced attractively at its recent level of US$103.13, or if the easy gains are already gone? This article walks through what the numbers actually say about value. The share price return data is mixed, with a 3.3% gain over the last 7 days, a 1.3% decline over 30 days, and longer term returns of 14.7% over 1 year, 180.5% over 3 years and 149.9% over 5 years. Recent coverage around Covista has focused on how investors are reassessing companies that have already...

ARS Pharmaceuticals (SPRY) opened FY 2025 with third quarter revenue of US$32.5 million and a basic EPS loss of US$0.52, alongside a net loss of US$51.2 million. This keeps the story firmly focused on the trade off between growth and profitability. The company has seen quarterly revenue move from US$7.97 million in Q1 2025 to US$15.7 million in Q2 2025 and then to US$32.5 million in Q3 2025. Basic EPS went from a loss of US$0.35 in Q1 to a loss of US$0.46 in Q2 and a loss of US$0.52 in Q3,...

Fresh off its FY 2025 third quarter update, Editas Medicine (EDIT) posted revenue of US$7.5 million with a basic EPS loss of US$0.28. Trailing 12 month figures show revenue of US$46.4 million and a basic EPS loss of US$2.35. Over recent quarters the company has seen revenue move from US$30.6 million in Q4 2024 to US$4.7 million in Q1 2025, US$3.6 million in Q2 2025 and US$7.5 million in Q3 2025. Basic EPS losses were US$0.55, US$0.92, US$0.63 and US$0.28 across those same periods as investors...

NPK International (NPKI) caught investor attention after reporting fourth quarter and full year 2025 results, moving from a prior year loss to profitability, alongside issuing full year 2026 revenue guidance. See our latest analysis for NPK International. The earnings release and 2026 revenue guidance appear to have come on the back of solid share price momentum, with a 90 day share price return of 7.26% and a year to date share price return of 14.71%. The 1 year total shareholder return of...

3D Systems (DDD) has opened FY 2025 with mixed results, as the latest third quarter showed revenue of US$91.2 million and a basic EPS loss of US$0.14, alongside a net income loss of US$18.1 million. The company has seen quarterly revenue move from US$113.3 million in Q2 2024 to US$112.9 million in Q3 2024, then to US$111.0 million in Q4 2024, before landing at US$94.5 million in Q1 2025, US$94.8 million in Q2 2025 and US$91.2 million in Q3 2025. EPS has swung between a loss of US$1.35 in Q3...

ZIM Integrated Shipping Services (NYSE:ZIM) FY 2025 Earnings Snapshot ZIM Integrated Shipping Services (NYSE:ZIM) has put out a mixed set of FY 2025 numbers so far, with Q3 revenue at US$1,777.2 million and EPS of US$1.02 against a trailing twelve month EPS of US$8.32. The company has seen revenue move from US$2,765.2 million in Q3 2024 to US$1,777.2 million in Q3 2025, while quarterly EPS shifted from US$9.34 to US$1.02 over the same period, giving investors a clear view of how the top and...